Search

Royalty Pharma PLC (Class A)

Open

BrancheGesundheitswesen

59.04 0.8

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

57.99

Max

59.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-61M

295M

Verkäufe

8.6M

631M

KGV

Branchendurchschnitt

30.639

62.58

EPS

1.3

Dividendenrendite

1.54

Gewinnspanne

46.733

Angestellte

100

EBITDA

112M

563M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+6.81% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

1.54%

2.19%

Nächstes Ergebnis

5. Aug. 2026

Nächste Dividendenausschüttung

10. Sept. 2026

Nächstes Ex-Dividendendatum

14. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.2B

33B

Vorheriger Eröffnungskurs

58.24

Vorheriger Schlusskurs

59.04

Nachrichtenstimmung

By Acuity

50%

50%

144 / 340 Ranking in Healthcare

Royalty Pharma PLC (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Juli 2026, 19:11 UTC

News
Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21. Juli 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20. Juli 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Peer-Vergleich

Kursveränderung

Royalty Pharma PLC (Class A) Prognose

Kursziel

By TipRanks

6.81% Vorteil

12-Monats-Prognose

Durchschnitt 62.4 USD  6.81%

Hoch 66 USD

Tief 58 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Royalty Pharma PLC (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Stimmung

By Acuity

144 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat